Creating new molecules to target and cleave specific proteins for cancer treatment.
Development of Caspase Cleavage Targeting Chimeras (CACTACs) for Targeted Protein Cleavage.
This study is looking at new ways to help cancer treatments work better by creating special molecules that can target and break down proteins that help cancer cells survive, which could lead to more effective options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11324155 on NIH RePORTER |
What this research studies
This research focuses on developing innovative molecules called caspase cleavage targeting chimeras (CACTACs) that can specifically cleave proteins involved in cancer cell survival. By utilizing a natural compound, piperlongumine, the researchers aim to enhance the effectiveness of existing cancer therapies by targeting proteins like Bcl-xL that help cancer cells evade death. The study will employ advanced technologies to identify the specific caspases involved in this process and explore how these molecules can be designed for optimal therapeutic effects. Patients may benefit from new treatment options that more effectively induce cancer cell death.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that express high levels of anti-apoptotic proteins like Bcl-xL.
Not a fit: Patients whose cancers do not involve the targeted proteins or those with advanced-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target and eliminate cancer cells.
How similar studies have performed: Other research has shown promise with similar approaches using targeted protein degradation strategies, indicating potential for success in this area.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Lyu, Dongwen — Augusta University
- Study coordinator: Lyu, Dongwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.